Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical BHVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Sep 20 | BB Squeeze + Upper Band Touch | Range Contraction | 0.00% |
| Sep 20 | Above Upper BB | Strength | 0.00% |
| Sep 20 | Up 3 Days in a Row | Strength | 0.00% |
| Sep 20 | Upper Bollinger Band Touch | Strength | 0.00% |
| Sep 19 | 20 DMA Support | Bullish | 4.56% |
| Sep 19 | Bollinger Band Squeeze | Range Contraction | 4.56% |
| Sep 19 | NR7 | Range Contraction | 4.56% |
| Sep 18 | Crossed Above 20 DMA | Bullish | 5.53% |
| Sep 18 | Crossed Above 50 DMA | Bullish | 5.53% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-13
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BHVN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 44.28 |
| 52 Week Low | 16.5 |
| Average Volume | 240,671 |
| 200-Day Moving Average | 31.905 |
| 50-Day Moving Average | 36.0254 |
| 20-Day Moving Average | 36.8295 |
| 10-Day Moving Average | 36.921 |
| Average True Range | 1.5893 |
| ADX | 15.72 |
| +DI | 26.7383 |
| -DI | 14.7344 |
| Chandelier Exit (Long, 3 ATRs ) | 34.2221 |
| Chandelier Exit (Short, 3 ATRs ) | 38.5279 |
| Upper Bollinger Band | 38.8614 |
| Lower Bollinger Band | 34.7976 |
| Percent B (%b) | 1.02 |
| BandWidth | 11.03409 |
| MACD Line | 0.4604 |
| MACD Signal Line | 0.3048 |
| MACD Histogram | 0.1556 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.4 Billion |
| Num Shares | 35.8 Million |
| EPS | -7.54 |
| Price-to-Earnings (P/E) Ratio | -5.17 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 5.62 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 42.06 | ||||
| Resistance 3 (R3) | 41.72 | 40.36 | 41.54 | ||
| Resistance 2 (R2) | 40.36 | 39.57 | 40.52 | 41.36 | |
| Resistance 1 (R1) | 39.65 | 39.08 | 40.01 | 39.99 | 41.19 |
| Pivot Point | 38.29 | 38.29 | 38.46 | 38.45 | 38.29 |
| Support 1 (S1) | 37.58 | 37.50 | 37.94 | 37.92 | 36.71 |
| Support 2 (S2) | 36.22 | 37.01 | 36.38 | 36.54 | |
| Support 3 (S3) | 35.51 | 36.22 | 36.36 | ||
| Support 4 (S4) | 35.85 |
